A Pilot Study of Daratumumab (CD38 Antagonist) in Patients With Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer

Trial Profile

A Pilot Study of Daratumumab (CD38 Antagonist) in Patients With Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Bladder cancer; Renal cell carcinoma; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 May 2018 Status changed from not yet recruiting to recruiting.
    • 11 Apr 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
    • 11 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top